Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)

Keros Therapeutics' Free Cash Flow history spans 7 years, with the latest figure at -$25.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 44.1% year-over-year to -$25.9 million; the TTM value through Dec 2025 reached $107.5 million, up 166.03%, while the annual FY2025 figure was $107.5 million, 166.03% up from the prior year.
  • Free Cash Flow reached -$25.9 million in Q4 2025 per KROS's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $160.6 million in Q1 2025 to a low of -$46.3 million in Q4 2024.
  • Average Free Cash Flow over 5 years is -$15.7 million, with a median of -$25.2 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 2162.62% in 2023, then skyrocketed 458.58% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$19.7 million in 2021, then dropped by 14.94% to -$22.7 million in 2022, then fell by 14.68% to -$26.0 million in 2023, then tumbled by 78.08% to -$46.3 million in 2024, then skyrocketed by 44.1% to -$25.9 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Free Cash Flow are -$25.9 million (Q4 2025), $1.8 million (Q3 2025), and -$29.1 million (Q2 2025).